THE GLOBAL CELL AND GENE THERAPY MARKET SIZE WAS VALUED AT USD 4.99 BILLION IN 2021 AND IS EXPECTED TO REACH USD 36.92 BILLION BY 2027, GROWING AT A CAGR OF 39.62% DURING 2021-2026

CELL AND GENE THERAPY MARKET REPORT INCLUDES SIZE, SHARE, & TRENDS ANALYSIS BY

  • Therapy Type: Gene Therapy and Cell Therapy
  • Application: Oncology, Genetic Disorders, Dermatology Disorders, Musculoskeletal Disorders, and Others)
  • End-Users: Hospitals, Cancer Care Centers, Wound Care Centers, and Others)
  • Geography: North America, Europe, APAC, Latin America, and the Middle East & Africa)

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2027

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

292 Pages

icon-table

84 Tables

icon-chart

132 Charts

icon-region

5 Regions

icon-country

19 Countries

icon-company

55 Companies

icon-market

4 Market Segment

CELL AND GENE THERAPY MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 36.92 BILLION (2027)
CAGR 39.62 % (2022-2027)
BASE YEAR 2021
FORECAST YEAR 2022-2027
MARKET SEGMENTS (Therapy Type) Gene Therapy and Cell Therapy
MARKET SEGMENTS (APPLICATION) Oncology, Genetic Disorders, Dermatology Disorders, Musculoskeletal Disorders, and Others
MARKET SEGMENTS (END-USER) Hospitals, Cancer Care Centers, Wound Care Centers, and Others
GEOGRAPHY COVERED North America, Europe, APAC, Latin America, and Middle East & Africa
COUNTRIES COVERED US, Canada, Germany, France, UK, Spain, Italy, Japan, China, South Korea, Australia, India, Brazil, Mexico, Turkey, Saudi Arabia, UAE, South Africa, Israel

MARKET OVERVIEW

The cell and gene therapy market was valued at USD 4.99 billion in 2021 and is expected to reach USD 36.92 billion by 2027, growing at a CAGR of 39.62% during the forecast period.

The global cell and gene therapy market is one of the fastest-growing segments of the global regenerative medicine market. The market is growing at a healthy rate and this trend is expected to continue during the forecast period. This surge can be attributable to the growing prevalence of various chronic diseases like cancer, cartilage-related problems, wounds, diabetic foot ulcer, genetic diseases, and other rare diseases across the globe.

Based on the product segments, the cell therapy market dominates the global industry. Further, based on applications, the oncology segment dominated the industry.

Gene therapy gathered the pace from last 2 decades because of the discovery of several genes responsible for mutation in various diseases. The advancement in this field and innovative technologies are giving a new era for biological therapeutics. Also, PRIME Designation and marketing authorization for products provide a new opportunity for the manufacturer's financing and revenue generation.

KEY HIGHLIGHTS

  • As per the American Society of Cell + Gene Therapy report in 2021, increasing the number of products, application rate, and products in clinical trials drive the market growth.
  • As per the Dive Biopharma report 2021, biotech companies who actively engaged in regenerative medicines and therapies reported USD 14 billion funding only in six months of 2021 which was reported to be USD 19.9 billion for the overall year.
  • In 2021, new 16 & 18 new products are in pipeline for cystic fibrosis and sickle cell respectively. The increasing burden of rare diseases and rising support from governmental authorities for rare diseases solutions is driving the global cell and gene therapy market growth.
  • In 2020, Gilead acquired Kite Pharma with a deal of USD 11.9 billion. After this acquisition company engaged in the expansion in the oncology segment to becoming a leader in the cell therapy industry.

CELL AND GENE THERAPY MARKET TRENDS & DRIVERS

  • In the gene therapy market, the most often cited acquisitions were that of bluebird bio and BioMarin. Also, Gilead Sciences, Biogen, Vertex, and other smaller companies turned to M&As to fill their product pipeline gap.
  • In the global cell & gene therapy market, manufacturers are becoming highly competitive in recent years due to the increasing demand for regenerative medicines and the rising opportunities for various cell & gene therapies.
  • In recent years, numerous high-value M&As clearly indicate that the major players in the pharmaceutical industry are looking at CAR T-cell therapies as an attractive growth opportunity for several players in the upcoming years.

INSIGHTS BY THERAPY TYPE

In 2020, around USD 2.3 billion in funding was reported only from private companies for gene therapies. Hence, the increased funding for gene therapies in small and medium manufacturing companies is propelling the growth of the market in recent years.

INSIGHTS BY APPLICATION

The increasing target gene therapies for dermatological disorders, rising demand for wound healing, and burnt skin treatment will drive the demand for cell & gene therapy solutions. In 2021, the Alliance Regenerative Medicine Report showed the increasing interest of manufacturers towards CGTs for dermatological diseases. As per the report, around 27 new products were in pipeline for dermatological diseases in 2021.

INSIGHTS BY END-USERS

The rising demand for advanced therapy medicinal products over traditional medicine, and revenue generation opportunities for healthcare systems and hospitals including cell & gene therapy manufacture with their own capital, and growing partnerships among biotech firms and hospitals are the major factors that are fueling the development across hospitals segment in the cell & gene therapy market.

INSIGHTS BY GEOGRAPHY

North America: High economic status and high expenditure on healthcare services drive the cell and gene therapy market in North America. National Health Institutes, industries, academic institutes, and hospitals are the significant contributors of sponsorship and financial funding for cell and gene therapy products.

Europe: The increasing funding is driving the Europe cell and gene therapy market growth consistently. Around USD 2.6 billion financings were reported in Europe for CGTs in 2020, which increased by 103% compared to previous years. In the cell therapy segment, USD 1.8 billion and in gene therapy, USD 2.3 billion funding accounted in 2020, which increased by 196% and 111% respectively

VENDOR LANDSCAPE

  • The key players in the cell and gene therapy market are Gilead Sciences, Novartis, Smith Nephew, Amgen, Organogenesis, Roche (Spark Therapeutics), Dendreon, Vericel, and Bristol-Myers Squibb Company.
  • An increasing number of mergers and acquisitions gives new potential to the industry growth. Gilead Sciences acquired Kite Pharma in 2020. Also, Novartis acquired Avexis in 2018, and Smith & Nephew acquired Osiris Therapeutics.
  • Although prominent vendors dominate the industry, they witness heavy competition from regional and local companies from India, China, Italy, the UK, and South Korea.

Frequently Asked Questions

How big is the global cell and gene therapy market?

The cell and gene therapy market size was valued at USD 4.99 billion in 2021 and is expected to reach USD 36.92 billion by 2027, growing at a CAGR of 39.62 % during the forecast period.

What are the latest trends in the cell and gene therapy market?

The latest trends are the expansion of manufacturing plants & technological advancement, expanding application for cell & gene therapies, growing demand for CAR T- cell therapies, and new products approvals & increasing pipeline products.

Who are the key players in the cell and gene therapy market?

The key players in the market are Gilead sciences, Novartis, Smith Nephew, Amgen, Organogenesis, Roche (Spark Therapeutics), Dendreon, Vericel, and Bristol-Myers Squibb Company.

What are the key areas where the global cell and gene therapy manufacturing companies should invest to sustain in the market?

Investing in R&D activities to develop novel therapies is key for the long-term sustainability of companies operating in the industry.

Which region has the largest share in the cell and gene therapy market?

North America has the largest share in the cell and gene therapy market.

Download Free Sample

The cell and gene therapy market size was valued at USD 4.99 billion in 2021 and is expected to reach USD 36.92 billion by 2027, growing at a CAGR of 39.62 % during the forecast period

The following factors are likely to contribute to the growth of the cell and gene therapy market –

  • Merger & Acquisition
  • Expansion of Manufacturing Plants & Technological Advancement
  • Expanding Application for Cell & Gene Therapies
  • Growing Demand for CAR T- Cell Therapies
  • New Products Approvals & Increasing Pipeline Products

Base Year: 2021

Forecast Year: 2022-2027

The study considers a detailed scenario of the present cell and gene therapy market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Key Vendors

  • Gilead sciences
    • Business Overview
    • Product Offerings
    • Key Strengths
    • Key Strategies
    • Key Opportunities
  • Novartis
  • Smith Nephew (Osiris Therapeutic)
  • Amgen
  • Organogenesis
  • Roche (Spark Therapeutics)
  • Dendreon
  • Vericel
  • Bristol-Myers Squibb

Other Prominent Vendors

  • Abeona Therapeutics
    • Business Overview
    • Product Offerings
  • APAC Biotech Pvt Ltd
  • Alnylam
  • Allovir
  • Tego Sciences
  • Avita Medical
  • Anterogen
  • AnGes Inc.
  • BioSolution Co. Ltd.
  • Cheisi Farmaceutici
  • CollPlant
  • CO.DON
  • Corestem
  • Bluebird Bio Inc
  • Stempeutics Research
  • GC Cell
  • Sanofi
  • Gensight biologics
  • Human Stem Cells Institute
  • JW CreaGene Co. Ltd
  • JCR Pharmaceuticals
  • Japan Tissue Engineering (J-TEC)
  • Kolon TissueGene
  • Medipost
  • MolMed
  • Nuvasive Inc.
  • Nipro Corporation
  • Orchard Therapeutics
  • Orthocell
  • Pfizer
  • Pharmicell
  • Sibiono Genetech
  • Shanghai Sunway Biotech
  • RMS Regenerative Medical System
  • Takeda Pharmaceuticals Company
  • Terumo

Upcoming Vendors

  • Biomarin Pharmaceutical
  • Bellicum Pharmaceutical
  • Castle Creek Biosciences Inc
  • Libella Gene Therapeutics
  • CARsgen Therapeutics
  • Hrain Biotechnology Co. Ltd
  • Helixmith
  • Krystal Biotech Inc.
  • JW Therapeutic
  • Poseida Therapeutics

Market segmentation by Therapy Type

  • Gene Therapy
  • Cell Therapy

Market segmentation by Application

  • Oncology
  • Genetic Disorders
  • Dermatology Disorders
  • Musculoskeletal Disorders
  • Others

Market segmentation by End-Users

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • Others

Market segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
  • APAC
    • Japan
    • China
    • South Korea
    • Australia
    • India
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • South Africa
    • Israel

1. RESEARCH METHODOLOGY
2. RESEARCH OBJECTIVES
3. RESEARCH PROCESS

4. SCOPE & COVERAGE
4.1. Market Definition
4.2. Base Year
4.3 Scope of The Study

5 REPORT ASSUMPTIONS & CAVEATS
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Overview

8 MARKET OPPORTUNITIES & TRENDS
8.1 Rising Number of Mergers & Acquisitions
8.2 Expansion of CGT Manufacturing Plants
8.3 Expanding Applications for Cell & Gene Therapies
8.4 Growing Demand for Car T-Cell Therapies

9 MARKET GROWTH ENABLERS
9.1 New Product Approvals & Increasing Pipeline of Products
9.2 Prime Designation & Funding Support For CGT
9.3 Rising Use of CGT Products for Disease Care
9.4 Increasing Use of CGT Products for Disease Treatment

10 MARKET RESTRAINTS
10.1 High Cost of Cell & Gene Therapies
10.2 Ethical Issues Regarding Genetical Material
10.3 Stringent Regulation for CGT Approvals

11 MARKET LANDSCAPE
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis

12 THERAPY
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Gene Therapy
12.4 Cell Therapy

13 APPLICATION
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Oncology
13.4 Genetic Disorders
13.5 Dermatology
13.6 Musculoskeletal Diseases
13.7 Other Diseases

14 END-USER
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.4 Cancer Care Centers
14.5 Wound Care Centers
14.6 Other End-Users

15 GEOGRAPHY
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview


16 NORTH AMERICA
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US
16.3.2 Canada

17 EUROPE
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 Germany
17.3.2 France
17.3.3 UK
17.3.4 Spain
17.3.5 Italy

18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Japan
18.3.2 China
18.3.3 South Korea
18.3.4 Australia
18.3.5 India

19 LATIN AMERICA
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Brazil
19.3.2 Mexico

20 MIDDLE EAST & AFRICA
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Turkey
20.3.2 Saudi Arabia
20.3.3 UAE
20.3.4 South Africa
20.3.5 Israel

21 COMPETITIVE LANDSCAPE
21.1 Competition Overview
21.2 Market Share Analysis

22 KEY COMPANY PROFILES
22.1 GILEAD SCIENCES
22.2 NOVARTIS
22.3 SMITH NEPHEW (OSIRIS THERAPEUTICS)
22.4 AMGEN
22.5 ORGANOGENESIS
22.6 ROCHE (SPARK THERAPEUTICS)
22.7 DENDREON
22.8 VERICEL
22.9 BRISTOL MEYER SQUIBB
22.9.1 Business Overview

23 OTHER PROMINENT VENDORS
23.1 ABEONA THERAPEUTICS
23.2 APAC BIOTECH PVT LTD
23.3 ALNYLAM
23.4 ALLOVIR
23.5 TEGO SCIENCES
23.6 AVITA MEDICAL
23.7 ANTEROGEN
23.8 ANGES INC
23.9 BIOSOLUTION CO. LTD
23.10 CHEISI FARMACEUTICI
23.11 COLLPLANT
23.12 CO.DON
23.13 CORESTEM
23.14 BLUEBIRD BIO INC
23.15 STEMPEUTICS RESEARCH
23.16 GC Cell
23.17 SANOFI
23.18 GENSIGHT BIOLOGICS
23.19 HUMAN STEM CELL INSTITUTE
23.20 JW CREAGENE CO. LTD
23.21 JCR PHARMACEUTICALS
23.22 JAPAN TISSUE ENGINEERING (J-TEC)
23.23 KOLON TISSUEGENE
23.24 MEDIPOST
23.25 MOLMED
23.26 NUVASIVE INC
23.27 NIPRO CORPORATION
23.28 ORCHARD THERAPEUTICS
23.29 ORTHOCELL
23.30 PFIZER
23.31 PHARMICELL
23.32 SIBIONO GENETECH
23.33 SHANGHAI SUNWAY BIOTECH
23.34 RMS REGENERATIVE MEDICAL SYSTEM
23.35 TAKEDA PHARMACEUTICALS COMPANY
23.36 TERUMO

24 Upcoming Market Vendors
24.1 BIOMARIN PHARMACEUTICALS
24.2 BELLICUM PHARMACEUTICALS
24.3 CASTLE CREEK BIOSCIENCES INC.
24.4 LIBELLA GENE THERAPEUTICS
24.5 CARSGEN THERAPEUTICS
24.6 HRAIN BIOTECHNOLOGY CO. LTD.
24.7 HELIXMITH
24.8 KRYSTAL BIOTECH INC.
24.9 JW THERAPEUTICS
24.10 POSEIDA THERAPEUTICS

25 REPORT SUMMARY
25.1 Key Takeaways
25.2 Strategic Recommendations

26 QUANTITATIVE SUMMARY

27 APPENDIX
27.1 Abbreviations

LIST OF EXHIBITS
Exhibit 1 Segmentation of Global Cell & Gene Therapy Market
Exhibit 2 Market Size Calculation Approach 2021
Exhibit 3 Cell Therapy Products in Pipeline 2021
Exhibit 4 Progress in Cell & Gene Therapy Products & Development
Exhibit 5 Impact of Rising Number of Mergers & Acquisitions
Exhibit 6 Impact of Expansion of CGT Manufacturing Plants
Exhibit 7 Impact of Expanding Applications for Cell & Gene Therapies
Exhibit 8 Impact of Growing Demand for CAR T-cell Therapies
Exhibit 9 Major Vendors Engaged in Development of CAR T-Cell Therapies
Exhibit 10 Impact of New Products Approvals & Increasing Pipeline of Products
Exhibit 11 Gene Therapies in Pipeline 2020 vs 2021
Exhibit 12 Impact of Prime Designation &Funding Support for CGT
Exhibit 13 Global Regenerative Medicine Financing 2019−2021 ($ billion)
Exhibit 14 Impact of Rising Use of CGT Products for Disease Care
Exhibit 15 Cell & Gene Therapy Products in Development 2020
Exhibit 16 Hematological Cancer Diseases Treated Patients by Cell & Gene Therapy 2018−2020
Exhibit 17 Impact of Increasing Use of CGT Products for Disease Treatment
Exhibit 18 Impact of High Cost of Cell & Gene Therapies
Exhibit 19 Impact of Ethical Issues Regarding Genetical Material
Exhibit 20 Risk Factors of Cell & Gene Therapy
Exhibit 21 Impact of Stringent Regulation for CGT Approvals
Exhibit 22 Global Cell & Gene Therapy Market 2021–2027 ($ billion)
Exhibit 23 Five Forces Analysis 2021


LIST OF TABLES
Table 1 Key Caveats
Table 2 Currency Conversion 2015−2021
Table 3 Cell & Gene Therapy Products Approved in 2020−2021
Table 4 Cell & Gene Therapy Products in Phase-III 2021
Table 5 Mergers & Acquisitions for Cell & Gene Therapy 2019−2021
Table 6 Expansion of Manufacturing Plants for Cell & Gene Therapy 2021
Table 7 Cell & Gene Therapy Products with Expanding Applications
Table 8 CAR T-Cell Investigational Products
Table 9 Cell & Gene Therapy Approved Products 2017−2021
Table 10 Cell & Gene Therapy Prime Designation Approved Products 2017−2021
Table 11 Cell & Gene Therapy Approved Products for Various Diseases
Table 12 Prices of Gene Therapies Marketed in Europe
Table 13 Approved Cell Therapy Products
Table 14 Cell & Gene Therapy Products for Genetic Disorders
Table 15 Global Cell & Gene Therapy Market by Geography 2021−2027 ($ million)
Table 16 Global Cell & Gene Therapy Market by Geography 2021−2027 (%)
Table 17 Approved Cell & Gene Therapy Products in Europe
Table 18 Approved Gene Therapy Products in Japan
Table 19 Development of Gene Therapies in China 2017
Table 20 Financing for Cell & Gene Therapy in Australia
Table 21 Cell & Gene Therapy Approved Products in Australia

Select a license type that suits your business needs

single-user Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date